Skip Navigation
Print This Page
Share this page: More

Search Results

A Phase I/II Study of 131I-Tositumomab in Patients with Relapsed/Refractory Hodgkin�??s Lymphoma
Protocol Number:
Phase I/II
Richard Wahl
This study is being done to find the highest safe dose of 131I-Tositumomab (Bexxar®) that can be given to patients who have Relapsed/Refractory Hodgkin?s lymphoma, what side effects these patients get when they take Bexxar® and if Bexxar® is effective in treating Relapsed/Refractory Hodgkin?s lymphoma. Bexxar® works by delivering doses of radiation to cancer cells.
-Hodgkin?s lymphoma that is relapsed or refractory -Prior bone marrow transplant or not able to have a bone marrow transplant -All stages and types of Hodgkin?s lymphoma -Age 18 or greater -Prior chemotherapy is allowed -Prior radiation therapy is allowed -Good physical condition -Average blood counts -Good organ function -Less than 25% of bone marrow involved with Hodgkin?s lymphoma -If female, not pregnant or breast feeding -Measurable disease
Bexxar® is a radiolabeled anti-CD20 monoclonal antibody composed of a radioisotope (Iodine 131) and an antibody (Tositumomab). The antibody recognizes and attaches to a protein on lymphoma cells and can kill these cells. The radioisotope (Iodine 131) can help the antibody kill cells better. Bexxar® is given through a vein in the arm. Bexxar® is given in an outpatient setting.
Last Update
08/28/2014 04:23 AM

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers


Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer